Praxis Precision Medicines Adds Director
Ticker: PRAX · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1689548
| Field | Detail |
|---|---|
| Company | Praxis Precision Medicines, Inc. (PRAX) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
Praxis Precision Medicines adds Dr. Steven M. Paul to its board.
AI Summary
Praxis Precision Medicines, Inc. announced on June 5, 2024, the election of Dr. Steven M. Paul to its Board of Directors. Dr. Paul brings extensive experience in drug development and has previously held leadership roles at various biotechnology companies. This appointment is part of the company's ongoing efforts to strengthen its board and guide its strategic direction.
Why It Matters
The addition of an experienced director like Dr. Paul can bring valuable insights and guidance to the company's drug development pipeline and strategic decision-making.
Risk Assessment
Risk Level: low — This filing is a routine corporate update regarding board composition and does not involve significant financial transactions or operational changes.
Key Players & Entities
- Praxis Precision Medicines, Inc. (company) — Registrant
- Dr. Steven M. Paul (person) — Newly elected Director
- June 5, 2024 (date) — Date of earliest event reported
FAQ
Who was elected to the Board of Directors of Praxis Precision Medicines, Inc.?
Dr. Steven M. Paul was elected to the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 5, 2024.
What is the principal executive office address of Praxis Precision Medicines, Inc.?
The principal executive office is located at 99 High Street, 30th Floor, Boston, Massachusetts 02110.
What is the telephone number for Praxis Precision Medicines, Inc.?
The telephone number is (617) 300-8460.
What is the SIC code for Praxis Precision Medicines, Inc.?
The Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Filing Stats: 924 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2024-06-06 17:09:08
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq Glo
Filing Documents
- prax-20240605.htm (8-K) — 50KB
- praxis-2020stockoptionandi.htm (EX-10.1) — 118KB
- 0001689548-24-000073.txt ( ) — 317KB
- prax-20240605.xsd (EX-101.SCH) — 2KB
- prax-20240605_lab.xml (EX-101.LAB) — 22KB
- prax-20240605_pre.xml (EX-101.PRE) — 13KB
- prax-20240605_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. As noted above, the Company's Annual Meeting was held on June 5, 2024, at which a quorum was present. The Company held its Annual Meeting to consider and vote on the four proposals set forth below, each of which is described in greater detail in the Proxy Statement. The final voting results are set forth below. Proposal 1 – Election of Class I Directors The Company's stockholders elected Dean Mitchell and Jill DeSimone to serve as Class I members of the Board of Directors of the Company (the "Board") until the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal, with the votes cast as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Vote Dean Mitchell 11,067,526 3,114,657 1,124,424 Jill DeSimone 10,861,923 3,320,260 1,124,424 Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company ' s Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 15,288,730 15,957 1,920 0 Proposal 3 - Amendment and Restatement of the 2020 Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the Company's 2020 Stock Option and Incentive Plan, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 9,080,631 5,097,843 3,709 1,124,424 Proposal 4 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 10,040,059 4,137,994 4,130 1,124,424
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Pra xis Precision Medicines, Inc. 2020 Stock Option and Incentive Plan , a s amended and restated . 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: June 6, 2024 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer